Bulletin
Investor Alert

New York Markets Open in:

NeuroBo Pharmaceuticals Inc.

NAS: NRBO

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Aug 8, 2022, 4:47 p.m.

/zigman2/quotes/207284462/composite

$

0.40

Change

+0.0004 +0.10%

Volume

Volume 4,200

Quotes are delayed by 20 min

/zigman2/quotes/207284462/composite

Previous close

$ 0.37

$ 0.39

Change

+0.02 +5.87%

Day low

Day high

$0.37

$0.40

Open

52 week low

52 week high

$0.34

$4.95

Open

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
07/24/2019 Charles L. Bisgaier
Chief Scientific Off. & Chair; Director
100,000   Award at $0 per share. 0
07/24/2019 Steven R. Gullans
President & CEO; Director
300,000   Award at $0 per share. 0
07/24/2019 Andrew H. Sassine
Director
15,000   Award at $0 per share. 0
07/24/2019 Seth Reno
Chief Commercial Officer
100,000   Award at $0 per share. 0
07/24/2019 Pedro Lichtinger
Director
15,000   Award at $0 per share. 0
07/24/2019 Kenneth W Kousky
Director
15,000   Award at $0 per share. 0
02/08/2018 Steven R. Gullans
President & CEO; Director
71,429   Acquisition at $7 per share. 500,003
02/08/2018 Seth Reno
Chief Commercial Officer
14,286   Acquisition at $7 per share. 100,002
08/14/2017 Jeffrey S. Mathiesen
Chief Financial Officer
3,207   Derivative/Non-derivative trans. at $3.59 per share. 11,513
08/10/2017 Jeffrey S. Mathiesen
Chief Financial Officer
3,000   Derivative/Non-derivative trans. at $3.59 per share. 10,770
08/10/2017 Jeffrey S. Mathiesen
Chief Financial Officer
3,000   Derivative/Non-derivative trans. at $3.59 per share. 10,770
07/31/2017 Charles L. Bisgaier
Chief Scientific Off. & Chair; Director
4,474   Derivative/Non-derivative trans. at $1.34 per share. 5,995
03/10/2017 Steven R. Gullans
President & CEO; Director
52,798   Acquisition at $9.47 per share. 499,997
03/10/2017 Andrew H. Sassine
Director
21,119   Acquisition at $9.47 per share. 199,996
03/10/2017 P. Kent Hawryluk
Director
25,000   Acquisition at $9.47 per share. 236,750
03/10/2017 Pedro Lichtinger
Director
10,559   Acquisition at $9.47 per share. 99,993
02/01/2017 Kenneth W Kousky
Director
110,428   0
02/01/2017 Kenneth W Kousky
Director
101,406   0
08/10/2016 Charles L. Bisgaier
Chief Scientific Off. & Chair; Director
51,750   Acquisition at $10 per share. 517,500
08/10/2016 Steven R. Gullans
President & CEO; Director
500,000   Acquisition at $10 per share. 5,000,000
08/10/2016 David Lowenschuss
Chief Legal Off. & Secretary
11,120   Acquisition at $10 per share. 111,200
08/10/2016 Mina Patel Sooch
President & CEO; Director
52,500   Acquisition at $10 per share. 525,000
08/10/2016 Seth Reno
Chief Commercial Officer
4,000   Acquisition at $10 per share. 40,000
08/10/2016 P. Kent Hawryluk
Director
25,000   Acquisition at $10 per share. 250,000
08/10/2016 Pedro Lichtinger
Director
10,000   Acquisition at $10 per share. 100,000
08/10/2016 Kenneth W Kousky
Director
1,000   Acquisition at $10 per share. 10,000
08/10/2016 Jeffrey S. Mathiesen
Chief Financial Officer
4,000   Acquisition at $10 per share. 40,000
08/10/2016 Charles L. Bisgaier
Chief Scientific Off. & Chair; Director
19,228   Derivative/Non-derivative trans. at $6.71 per share. 129,019
08/10/2016 Charles L. Bisgaier
Chief Scientific Off. & Chair; Director
16,144   Derivative/Non-derivative trans. at $6.71 per share. 108,326
08/10/2016 Charles L. Bisgaier
Chief Scientific Off. & Chair; Director
59,561   Derivative/Non-derivative trans. at $0 per share. 0
08/10/2016 Steven R. Gullans
President & CEO; Director
306,025   Derivative/Non-derivative trans. at $6.71 per share. 2,053,427
08/10/2016 Mina Patel Sooch
President & CEO; Director
27,141   Derivative/Non-derivative trans. at $6.71 per share. 182,116
08/10/2016 Mina Patel Sooch
President & CEO; Director
11,078   Derivative/Non-derivative trans. at $0 per share. 0
08/10/2016 Daniela Carmen Oniciu
Vice President
2,237   Derivative/Non-derivative trans. at $0 per share. 0
08/10/2016 Andrew H. Sassine
Director
31,853   Derivative/Non-derivative trans. at $6.71 per share. 213,733
08/10/2016 Andrew H. Sassine
Director
75,080   Derivative/Non-derivative trans. at $0 per share. 0
08/10/2016 P. Kent Hawryluk
Director
23,616   Derivative/Non-derivative trans. at $6.71 per share. 158,463
08/10/2016 P. Kent Hawryluk
Director
7,457   Derivative/Non-derivative trans. at $0 per share. 0
08/10/2016 Pedro Lichtinger
Director
39,274   Derivative/Non-derivative trans. at $6.71 per share. 263,528
08/10/2016 Kenneth W Kousky
Director
116,891   Derivative/Non-derivative trans. at $6.71 per share. 784,338
08/10/2016 Kenneth W Kousky
Director
95,439   Derivative/Non-derivative trans. at $0 per share. 0
08/10/2016 Jeffrey S. Mathiesen
Chief Financial Officer
3,927   Derivative/Non-derivative trans. at $6.71 per share. 26,350
08/10/2016 Charles L. Bisgaier
Chief Scientific Off. & Chair; Director
6,515   43,715
08/10/2016 Mina Patel Sooch
President & CEO; Director
1,212   8,132
08/10/2016 Daniela Carmen Oniciu
Vice President
245   1,643
08/10/2016 Andrew H. Sassine
Director
8,212   55,102
08/10/2016 P. Kent Hawryluk
Director
816   5,475
08/10/2016 Kenneth W Kousky
Director
10,439   70,045
/news/latest/company/us/nrbo

MarketWatch News on NRBO

  1. Gemphire Therapeutics' stock extends slide, plummets 39% premarket after trial halt

    7:24 a.m. Aug. 10, 2018

    - Tomi Kilgore

  2. Gemphire's stock on track to open at record low

    7:24 a.m. Aug. 10, 2018

    - Tomi Kilgore

  3. Gemphire Therapeutics stock tumbles 17% premarket after trial halt

    7:01 a.m. Aug. 10, 2018

    - Tomi Kilgore

  4. Gemphire's stock on track to open at record low

    7:02 a.m. Aug. 10, 2018

    - Tomi Kilgore

  5. Gemphire Therapeutics downgraded to market perform from outperform at Raymond James

    8:11 a.m. Aug. 7, 2018

    - Tomi Kilgore

  6. Gemphire Therapeutics stock price target raised to $26 from $22 at Raymond James

    8:14 a.m. June 29, 2018

    - Tomi Kilgore

  7. Gemphire Therapeutics started at outperform with $22 stock price target

    8:19 a.m. May 16, 2018

    - Tomi Kilgore

/news/nonmarketwatch/company/us/nrbo

Other News on NRBO

  1. 10-Q: NEUROBO PHARMACEUTICALS, INC.

    4:38 p.m. May 13, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  2. 10-K: NEUROBO PHARMACEUTICALS, INC.

    5:20 p.m. March 31, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  3. ETRN, PIXY and UONE among mid-day movers

    1:48 p.m. Jan. 25, 2022

    - Seeking Alpha

  4. Healthcare names dominate premarket losers list

    9:19 a.m. Jan. 4, 2022

    - Seeking Alpha

  5. 10-Q: NEUROBO PHARMACEUTICALS, INC.

    9:39 a.m. Nov. 15, 2021

    - Edgar Online - (EDG = 10Q, 10K)

  6. STAB, RLX and GWH among mid-day movers

    12:31 p.m. Oct. 13, 2021

    - Seeking Alpha

  7. CLLS, BBIG and GNLN among pre market gainers

    8:26 a.m. Oct. 13, 2021

    - Seeking Alpha

  8. ADVM, SELB and OSUR among pre market gainers

    8:22 a.m. Oct. 4, 2021

    - Seeking Alpha

  9. OMER, SMTS and AVIR among mid-day movers

    1:18 p.m. Oct. 1, 2021

    - Seeking Alpha

  10. NeuroBo Pharmaceuticals falls 11% amid $14M equity offering

    8:20 a.m. Oct. 1, 2021

    - Seeking Alpha

  11. SD, TELL and CEI among pre market gainers

    8:26 a.m. Sept. 28, 2021

    - Seeking Alpha

  12. 7 Biotech Stocks to Buy That Have Millionaire-Maker Potential

    12:19 p.m. Sept. 10, 2021

    - InvestorPlace.com

  13. DQ, BTBT and GOTU among pre market gainers

    8:34 a.m. Sept. 2, 2021

    - Seeking Alpha

  14. 10-Q: NEUROBO PHARMACEUTICALS, INC.

    8:27 a.m. Aug. 16, 2021

    - Edgar Online - (EDG = 10Q, 10K)

  15. SAVA, MMAT, XAIR among midday movers

    1:03 p.m. July 21, 2021

    - Seeking Alpha

  16. Loading more headlines...
/news/pressrelease/company/us/nrbo

Press Releases on NRBO

  1. NeuroBo Pharmaceuticals Reports Full Year 2021 Financial Results

    8:00 a.m. April 1, 2022

    - PR Newswire - PRF

  2. NeuroBo Pharmaceuticals Reports Third Quarter 2021 Financial Results

    9:00 a.m. Nov. 15, 2021

    - PR Newswire - PRF

  3. Friday Sector Laggards: Biotechnology, Diagnostics

    1:39 p.m. Oct. 1, 2021

    - MarketNewsVideo.com

  4. NeuroBo Pharmaceuticals Reports Second Quarter 2021 Financial Results

    8:00 a.m. Aug. 16, 2021

    - PR Newswire - PRF

  5. EVIO Inc. (EVIO) Expands Footprint to Los Angeles

    12:18 p.m. June 4, 2018

    - NetworkNewsWire

Link to MarketWatch's Slice.